TGTX · NASDAQ · STOCK
TG Therapeutics, Inc.
$49.86
52W $26.05 – $59.30
60/100
$7.64B
16.4
1.67
Is TGTX Bullish or Bearish?
Mixed.
Innellis AI committee rates TG Therapeutics, Inc. (TGTX) Watch with a composite score of 60/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +0.28 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -19.72 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 1.78 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
60/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 49%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 72.3% shows genuine earnings power backing the valuation
− Price-to-book of 21.1x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 76.1% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 22.5% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
42.0
Neutral
MACD Histogram
-0.641
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$32.72
Resistance
$59.30
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$50.30
Below
EMA 21
$51.63
Below
EMA 50
$50.05
Below
EMA 200
$40.74
Above
Fundamental Analysis
Valuation
65
Profitability
100
Financial Health
81
Cash Flow
15
Valuation
P/E Ratio
16.4×
P/B Ratio
11.71×
PEG Ratio
0.03
Dividend Yield
0.00%
52W High
$59.30
52W Low
$26.05
Quality & Growth
ROE
6900.7%
ROA
4205.8%
Gross Margin
8236.5%
Operating Margin
1705.1%
Revenue Growth YoY
—
Debt / Equity
1.25
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 16.4 (inexpensive relative to a 15-40x range); Price-to-book of 11.7x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 69.0%; Return on assets of 42.1%; Net margin of 55.2%; Gross margin of 82.4%; Current ratio of 4.27 (healthy short-term liquidity); Debt-to-equity of 1.25; Free cash flow per share is negative (-0.00); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full TGTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →